City Therapeutics, Inc.
NNASDAQ:CTY20.77
USD
+0.34
(+1.66%)
CIK
2143850
ISIN
US1787821081
CUSIP
178782108
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Andrew C. Orth
- Full Time Employees
- 75
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 399 Binney Street Cambridge MA United States 02142
- IPO Date
- Oct 16, 2026
- CIK
- 0002143850
- Website
- citytx.com
- Similar Companies
- Business
- City Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the development of RNAi therapeutics. The company was founded by John Maraganore, Sebastian Trousil, Ari Nowacek, Mark Keating, Kotaro Nakanishi, Yukihide Tomari, and Phillip Zamore on July 17, 2023 and is headquartered in Cambridge, MA.
Company News
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
City Therapeutics Announces Pricing of Upsized Initial Public Offering
City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push
City Therapeutics, RNAi Treatment Developer, Files For IPO
Baby Bonds Complete Review